O2MATIC-ACUT: Automated Oxygen Control by O2matic to Patients Admitted With Acute Hypoxemia

Sponsor
Hvidovre University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04079465
Collaborator
Innovation Fund Denmark (Other)
150
2
2
39
75
1.9

Study Details

Study Description

Brief Summary

The aim of this study is to examine if automated oxygen delivery with O2matic allows for faster weaning from oxygen supply and better oxygen control than manually controlled oxygen therapy for patients admitted to the emergency department with acute hypoxemia. Furthermore it will be tested if O2matic compared to manual control allows for earlier discharge.

Condition or Disease Intervention/Treatment Phase
  • Device: O2matic
N/A

Detailed Description

Closed-loop control of oxygen therapy is described in the literature used for preterm infants, trauma patients, medical emergency use, and for patients with Chronic Obstructive Pulmonary Disease (COPD). O2matic is a closed-loop system that is based on continuous and non-invasive measurement of pulse rate and oxygen-saturation (SpO2). The algorithm in O2matic controls oxygen delivery with the aim of keeping the SpO2 within the desired interval, which could be 88-92 % for patients at risk of hypercapnia or 94-98 % for patients with pneumonia, asthma exacerbation, heart failure and other medical emergencies, according to guidelines from British Thoracic Society (BTS). SpO2-interval can be set for the individual patients, as can the range of acceptable oxygen-flow. If SpO2 or oxygen-flow cannot be maintained within the desired intervals an alarm will sound.

All studies on closed-loop systems have shown that this method is better than manually control by nurse to maintain saturation within the desired interval. Furthermore, some studies have indicated that closed-loop has the possibility to reduce admission time and to reduce time spent with oxygen therapy, due to more efficient and faster withdrawal from oxygen supplementation.

In the present study O2matic will be tested versus manual control, for patients admitted to the emergency department with acute hypoxemia due to any reason, except for carbon monoxide (CO) poisoning and other conditions where SpO2 is not a reliable measure of hypoxemia. During the study the patients will either have oxygen controlled with O2matic or manually by nursing staff for 24 hours or until discharge or weaning from oxygen supply. All patients will have continuous logging of pulse rate, oxygen-saturation and oxygen-flow with O2matic, but only in the O2matic active group, the algorithm will control oxygen-delivery.

The primary hypothesis is that O2matic compared to manual control allows for faster weaning from oxygen supplementation, and that more patients will be weaned from oxygen supplementation within a time frame of 24 hours. Furthermore it will be tested if O2matic compared to manual control allows for earlier hospital discharge. It will be tested if O2matic is better than manual control in maintaining oxygen-saturation within the desired interval and reducing time with unintended hypoxia and hyperoxia.

No safety issues has been reported in the literature. O2matic is approved in Europe with "Conformité Européenne" (CE) mark, and approved for clinical testing by The Danish Medicines Agency, The Ethics Committee in the Capital Region of Denmark and by the regional Data Protection Board. The study will be conducted according to Good Clinical Practice (GCP) standards with independent monitoring. All adverse events and serious adverse events will be monitored and serious adverse events will be reported to Danish Medicines Agency.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Open label randomized controlled parallel studyOpen label randomized controlled parallel study
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Automated Oxygen Control by O2matic to Patients Admitted With Acute Hypoxemia
Actual Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: O2matic

Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation

Device: O2matic
O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.

No Intervention: Manual

Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.

Outcome Measures

Primary Outcome Measures

  1. Probability of weaning from oxygen within 24 hours [24 hours]

    Fraction of patients weaned from oxygen supplementation within 24 hours

Secondary Outcome Measures

  1. Probability of weaning from oxygen within 12 hours [12 hours]

    Fraction of patients weaned from oxygen supplementation within 12 hours

  2. Duration of admission [30 days]

    Time from admission to emergency department to discharge from hospital

  3. Time within SpO2 target interval [24 hours]

    Fraction of time within prescribed SpO2 interval in O2matic and manual arm

  4. Time with minor hypoxemia [24 hours]

    Fraction of time with SpO2 at 1 to 3 percentage points below target interval

  5. Time with severe hypoxemia [24 hours]

    Fraction of time with SpO2 at 4 or more percentage points below target interval

  6. Time with hyperoxia [24 hours]

    Fraction of time with SpO2 above target interval in O2matic and manual arm

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admission with hypoxemic respiratory failure

  • Age >= 18 years

  • Expected duration of admission > 24 hours

  • Need for oxygen supplementation to maintain SpO2 >= 88 % (patients at risk of hypercapnia) or SpO2 >= 94 % (other patients)

  • Cognitively able to participate in the study

  • Willing to participate and give informed consent

Exclusion Criteria:
  • Need or anticipated need for mechanical ventilation (intermittent Continuous Positive Airway Pressure (CPAP) is allowed)

  • Patients with CO-poisoning or other condition with unreliable SpO2.

  • Patients in need of oxygen supplementation at more than 10 liters/min

  • Pregnancy

  • Cognitive or language barriers for participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amager Hospital Copenhagen Denmark 2300
2 Hvidovre Hospital Hvidovre Denmark 2650

Sponsors and Collaborators

  • Hvidovre University Hospital
  • Innovation Fund Denmark

Investigators

  • Study Chair: Ove Andersen, DMSc, Hvidovre University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ejvind Frausing Hansen, Senior Consultant, Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT04079465
Other Study ID Numbers:
  • O2MATIC-ACUTE
First Posted:
Sep 6, 2019
Last Update Posted:
Dec 29, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ejvind Frausing Hansen, Senior Consultant, Hvidovre University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 29, 2021